title: 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
abstract: OBJECTIVE
  The purpose of this work was to investigate the prognostic value of response analysis using early 3'-deoxy-3'-[(18)F]-fluorothymidine ((18)F-FLT) PET/CT in esophageal squamous cancer patients and make a comparison with [(18)F]-fluorodeoxyglucose ((18)F-FDG) PET/CT.
  
  
  METHODS
  For 34 patients with esophageal squamous cell cancer, both (18)F-FLT PET/CT and (18)F-FDG PET/CT scans were performed at baseline (pre), 4 weeks after the start of radiotherapy or chemoradiotherapy (interim), and 2 weeks after therapy completion (final). SUVmax1, SUVmax2, and SUVmax3 represent SUVmax (SUV: standard uptake values) measured on the pre, interim, and final scans, respectively. GTVFLT-PET and GTVFDG-PET (GTV: gross tumor volume) were measured on the pre and interim scans. ΔSUV/ΔGTV represents the fractional changes of SUVmax/GTV between two different time points. PET parameters were evaluated for correlations with outcome.
  
  
  RESULTS
  Regarding (18)F-FLT PET/CT, according to receiver operating characteristic (ROC) curve analysis, parameters for predicting 2-year progression-free survival (PFS) and locoregional control (LRC) showed the highest area under curve (AUC) on interim (18)F-FLT PET/CT scans (ΔSUV12, AUC of 0.812 for PFS, 0.775 for LRC, with a cutoff of 60 %; P = 0.008), compared with the parameters on pre and final scans. Patients with a ΔSUV12 greater than 60 %, who were defined as interim PET-negative group, were associated with better 2-year PFS and LRC than the interim PET-positive group (PFS: 70.6 % vs. 35.2 %, P = 0.025; LRC: 84.2 % vs 52.9, P = 0.046). In terms of (18)F-FDG PET/CT, ΔSUV13 on the final 18F-FDG PET/CT scan demonstrated better prediction (AUC of 0.812 for PFS, 0.807 for LRC, with a cutoff of 75 %; P = 0.016) than the parameters on pre and interim scans. An SUVmax decrease ≥ 75 % on the final (18)F-FDG PET/CT scan was associated with better clinical outcome (PFS: 73.3 % vs. 36.8 %, P = 0.022; LRC: 86.7 % vs 52.6, P = 0.029). These correlations were most prominent in the subgroup of patients treated with chemoradiotherapy.
  
  
  CONCLUSIONS
  Early interim (18)F-FLT PET/CT is a significant predictor of 2-year PFS and LRC, which is correlated better with early responses and late outcomes than interim (18)F-FDG PET/CT in esophageal squamous cancer patients.
authors.affiliation: Department of Nuclear Medicine, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, China, leochen0821@stu.xmu.edu.cn.
authors.forename: Haojun
authors.initials: H
authors.lastname: Chen
authors.forename: Yimin
authors.initials: Y
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Wu
authors.forename: Long
authors.initials: L
authors.lastname: Sun
authors.forename: Qin
authors.initials: Q
authors.lastname: Lin
authors.forename: Long
authors.initials: L
authors.lastname: Zhao
authors.forename: Hanxiang
authors.initials: H
authors.lastname: An
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D015224:Dideoxynucleosides; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D012372:ROC Curve; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: D015224:Dideoxynucleosides; D019788:Fluorodeoxyglucose F18; C002854:alovudine